Previous Close | 41.85 |
1-Year Change | 57.27% |
6-Months Change | -0.71% |
3-Months Change | 17.26% |
Moving Avg (50d) | 38.36 |
Moving Avg (200d) | 38.664 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.98M |
Beta (3-Years) | 1.31 |
Revenue Growth (ttm) | 304.92% |
Net Profit Margin (ttm) | -2.86% |
Return On Assets (ttm) | -0.04% |
EPS (ttm) | -2.65 |
PE Ratio (ttm) | -15.79 |
Dividend Yield | % |
Asset Description: | Celldex Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-17 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
42.687 | 43.942 | 44.779 | 46.035 | 48.127 | 50.22 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |